Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.50 |
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.49 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470405 | 0.88 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL3180524 | 0.87 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11CCNC | |
| SCHEMBL4471507 | 0.82 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL3182691 | 0.82 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11CCNC | |
| SCHEMBL5477709 | 0.82 | CDK8 (0.53) | MAPK14MAPK13MAPK12MAPK11CCNC | |
| SCHEMBL5474959 | 0.81 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL13791926 | 0.80 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11CCNC | |
| SCHEMBL3877859 | 0.79 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11CCNC | |
| SCHEMBL4603451 | 0.79 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3170749 | 0.78 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11CCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010529-A1 | Nitrogenous heterocyclic compounds and medical use thereof | MAPK1, NOS1, NOS2 | MAPK14 12/4885MAPK13 5/4885MAPK12 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.